Last reviewed 2026-06-02 · How we verify

nangibotide high dose

Inotrem · Phase 2 active Small molecule ✓ Verified Jun 2026

nangibotide high dose is a Small molecule drug developed by Inotrem. It is currently in Phase 2 development. Also known as: LR12.

Nangibotide is a protein modality inhibitor of the triggering receptor expressed on myeloid cells 1, which is being studied in high doses for the treatment of septic shock. Clinical trials have investigated nangibotide in patients with septic shock, comparing its efficacy and safety to a placebo.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	nangibotide high dose
Also known as	LR12
Sponsor	Inotrem
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

nangibotide high dose CI brief — competitive landscape report
nangibotide high dose updates RSS · CI watch RSS
Inotrem portfolio CI

Frequently asked questions about nangibotide high dose

What is nangibotide high dose?

nangibotide high dose is a Small molecule drug developed by Inotrem.

Who makes nangibotide high dose?

nangibotide high dose is developed by Inotrem (see full Inotrem pipeline at /company/inotrem).

Is nangibotide high dose also known as anything else?

nangibotide high dose is also known as LR12.

What development phase is nangibotide high dose in?

nangibotide high dose is in Phase 2.

Manufacturer: Inotrem — full pipeline
Also known as: LR12

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing